Even As Acting US FDA Commissioner, Woodcock Still Holds Multiple Positions
To help with the transition to Biden’s COVID-19 response, Woodcock will retain some therapeutic development duties in the program the Trump administration had called Operation Warp Speed.
You may also be interested in...
Julie Tierney will become CBER’s deputy director for strategy, policy and legislation, a newly created position.
The announcement of US FDA Deputy Commissioner’s new focus going forward at the agency may not mean what you think it does. The focus shouldn’t be on what Janet Woodcock is not doing – but on the fact that she is staying on at the agency at all.
Woodcock’s willingness to stay on at US FDA for more than a transitional period after Robert Califf’s expected confirmation as commissioner may depend on exactly the type of authority and tasks he’d be willing to delegate to her. Plus, some other agency personnel updates.